Also known as: CC-92480
Mezigdomide is a CELMoD agent in development for multiple myeloma, including relapsed or refractory disease settings. Its program includes Phase 3 SUCCESSOR trials in combination regimens. It is not FDA approved.
An interim phase 3 analysis showed mezigdomide plus carfilzomib and dexamethasone reduced the risk of progression or death in relapsed/refractory multiple myeloma. The SUCCESSOR-2 study remains ongoing and will assess overall survival and safety.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Novel CELMoD agents are being evaluated to address T-cell exhaustion in multiple myeloma patients, while CAR T-cell therapy CARVYKTI shows longer-term survival benefits. Nearly 200,000 people in the U.S. live with this blood cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07356154 |
A Study of Revumenib and Mezigdomide in People With Leukemia |
RECRUITING | PHASE1/PHASE2 |
| NCT07355335 |
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML |
NOT_YET_RECRUITING | PHASE1 |
| NCT07105059 |
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma |
RECRUITING | PHASE1 |
| NCT07032714 |
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma |
RECRUITING | PHASE1 |
| NCT06994117 |
Expanded Access for Mezigdomide |
AVAILABLE | |
| NCT06988488 |
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma |
RECRUITING | PHASE1/PHASE2 |
| NCT06645678 |
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma |
RECRUITING | PHASE1/PHASE2 |
| NCT06627751 |
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease |
RECRUITING | PHASE2 |
| NCT06318676 |
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment |
COMPLETED | PHASE1 |
| NCT06163898 |
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma |
TERMINATED | PHASE1 |
